KORU Medical Systems, Inc.

KORU Medical Systems, Inc. Investor Briefing: Leadership Transition and Future Outlook

A new era is dawning at KORU Medical Systems. The medical technology company, known for its innovative subcutaneous infusion solutions, recently announced a pivotal leadership transition set to redefine its strategic direction. This summary delves into the key aspects of this change and its implications for investors.

Company Overview: KORU Medical Systems (NASDAQ: KORU) develops, manufactures, and commercializes innovative subcutaneous infusion solutions. Its primary product, the FREEDOM Infusion System, improves the quality of life for patients needing subcutaneous immunoglobulin (SCIg) therapy and other subcutaneous treatments. This growing market is fueled by the rising prevalence of chronic conditions and increasing demand for home-based care.

The Leadership Transition: On March 12, 2026, KORU Medical Systems announced the retirement of Linda Tharby, its President and CEO. To ensure a smooth transition, the Board of Directors appointed Adam Kalbermatten as the new President, effective March 15, 2026. He will officially become Chief Executive Officer on July 1, 2026, after Ms. Tharby steps down from the CEO position on June 30, 2026. Ms. Tharby will continue in an advisory role and remain on the Board of Directors until December 31, 2026, to assist with the transition. Mr. Kalbermatten is also expected to join the Board in 2027.

Why This Matters for Investors:

1. Strategic Direction and Growth: Leadership changes often signal a potential shift in company strategy. While KORU has focused on expanding its FREEDOM Infusion System and exploring new applications, Mr. Kalbermatten's appointment suggests the Board seeks fresh perspectives to accelerate growth, enhance product innovation, and potentially explore new market opportunities or operational efficiencies. Investors will want to understand his vision for KORU's future, especially regarding market expansion, product pipeline development, and profitability initiatives.

2. New Leadership Profile: Adam Kalbermatten brings a strong background in the medical device industry, having held leadership roles at companies like Medtronic and Johnson & Johnson. His experience in commercial strategy, product development, and global market penetration within complex healthcare environments directly applies to KORU's business. This expertise could prove instrumental in navigating competitive landscapes and driving KORU's next growth phase.

3. Financial Implications and Compensation Details:

   • Adam Kalbermatten's Compensation: As President and incoming CEO, Mr. Kalbermatten's compensation package reflects his pivotal role. His compensation package includes an annual base salary of $550,000, a target annual bonus opportunity of 75% of his base salary (based on company and individual performance), and substantial long-term incentive awards. These awards comprise a one-time grant of restricted stock units (RSUs) valued at $1,500,000, vesting over three years, and an annual long-term incentive award target of $1,500,000. This annual award is typically granted as a mix of performance share units (PSUs) and stock options, linked to specific performance metrics and vesting schedules. This structure directly aligns his incentives with shareholder value creation.
   • Linda Tharby's Retirement Package: Ms. Tharby's retirement package includes continued vesting of certain equity awards during her advisory period, health benefits, and a severance payment consistent with her existing employment agreement. The 8-K filing details the specifics of her remaining equity awards and severance terms, designed to recognize her contributions and ensure a smooth departure.

4. Risk and Opportunity: While an orderly transition with an experienced leader is generally positive, any CEO change carries inherent risks. These include potential disruption to ongoing initiatives, integration challenges, and the time a new leader needs to fully implement their vision. However, it also presents an opportunity for renewed focus, accelerated innovation, and potentially a re-rating of the company's stock if the new leadership successfully executes its strategic objectives.

What's Next for Investors: Investors should closely monitor Mr. Kalbermatten's initial communications and presentations, especially during upcoming earnings calls or investor events. Key indicators will include his strategic priorities, any changes to KORU's operational focus, and specific targets for revenue growth, profitability, and product development. The market's reaction to his leadership and the company's performance under his guidance will be critical for assessing this transition's long-term impact. As always, this leadership change represents one piece of the investment puzzle. A comprehensive review of KORU's financial health, market position, competitive landscape, and overall industry trends remains essential for informed decision-making.